Shun Lü
Impact in
- Pulmonary and Respiratory Medicine top 0.02%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Oncology top 0.05%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
Papers in
-
- Lung Cancer Treatments and Mutations 239
- Lung Cancer Diagnosis and Treatment 55
- Gastric Cancer Management and Outcomes 19
- Oncology 171
- Cancer Immunotherapy and Biomarkers 61
- Lung Cancer Research Studies 50
- Colorectal Cancer Treatments and Studies 38
- HER2/EGFR in Cancer Research 15
- Co-authors
- Yi-Long Lung Cancer Wu (40 shared papers)Caicun Zhou (14 shared papers)Chengping Hu (12 shared papers)Jifeng Feng (10 shared papers)Wei Li (6 shared papers)Yongfeng Yu (49 shared papers)Chong‐Rui Xu (4 shared papers)Yunchao Huang (4 shared papers)
- Journals
- Annals of Oncology (57 papers)Journal of Thoracic Oncology (57 papers)Lung Cancer (29 papers)Journal of Clinical Oncology (17 papers)Translational Lung Cancer Research (10 papers)
- Partner nations
- ChinaUnited StatesSouth Korea
In The Last Decade
Shun Lü
437 papers receiving 28.7k citations
Shun Lü's Hit Papers
Peers
Comparison fields: 5 of 181
- Pulmonary and Respiratory Medicine 16.9k
- Oncology 13.2k
- Cancer Research 3.4k
- Molecular Biology 5.4k
- Immunology 1.2k
Countries citing papers authored by Shun Lü
This map shows the geographic impact of Shun Lü's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shun Lü with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shun Lü more than expected).
Fields of papers citing papers by Shun Lü
This network shows the impact of papers produced by Shun Lü. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shun Lü. The network helps show where Shun Lü may publish in the future.
Co-authors
The 25 scholars most cited alongside Shun Lü, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 467 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Hit paper breakdown → | 2011 | 3516 |
| 2 | Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial Hit paper breakdown → | 2019 | 2691 |
| 3 | Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial Hit paper breakdown → | 2014 | 1736 |
| 4 | Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials Hit paper breakdown → | 2015 | 1348 |
| 5 | Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer Hit paper breakdown → | 2020 | 1288 |
| 6 | First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial Hit paper breakdown → | 2021 | 1061 |
| 7 | Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial Hit paper breakdown → | 2016 | 991 |
| 8 | First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study Hit paper breakdown → | 2015 | 624 |
| 9 | The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti–Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC Hit paper breakdown → | 2019 | 470 |
| 10 | Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial Hit paper breakdown → | 2017 | 439 |
| 11 | Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC Hit paper breakdown → | 2023 | 402 |
| 12 | Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802) Hit paper breakdown → | 2015 | 401 |
| 13 | Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial Hit paper breakdown → | 2015 | 364 |
| 14 | IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy Hit paper breakdown → | 2020 | 331 |
| 15 | BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non–Small-Cell Lung Cancer Hit paper breakdown → | 2015 | 311 |
| 16 | 2019 | 302 | |
| 17 | Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer Hit paper breakdown → | 2021 | 299 |
| 18 | Perioperative Nivolumab in Resectable Lung Cancer Hit paper breakdown → | 2024 | 288 |
| 19 | 2018 | 264 | |
| 20 | Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial Hit paper breakdown → | 2023 | 256 |
About Shun Lü
Shun Lü is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Molecular Biology and Pathology and Forensic Medicine, having authored 467 papers that have together received 29.2k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (239 papers), Cancer Immunotherapy and Biomarkers (61 papers), Lung Cancer Diagnosis and Treatment (55 papers), Lung Cancer Research Studies (50 papers), Colorectal Cancer Treatments and Studies (38 papers), Cancer Genomics and Diagnostics (27 papers), Gastric Cancer Management and Outcomes (19 papers) and HER2/EGFR in Cancer Research (15 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (16.9k citations), Oncology (13.2k citations), Cancer Research (3.4k citations), Molecular Biology (5.4k citations) and Immunology (1.2k citations). Shun Lü has collaborated with scholars based in China, United States and South Korea. Frequent co-authors include Yi-Long Lung Cancer Wu, Caicun Zhou, Chengping Hu, Jifeng Feng, Wei Li, Yongfeng Yu, Chong‐Rui Xu, Yunchao Huang, Mei Hou and Dan Massey. Their work appears in journals such as Annals of Oncology, Journal of Thoracic Oncology, Lung Cancer, Journal of Clinical Oncology and Translational Lung Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.